Corporate structures are often a giveaway. Of strategy, culture, growth, and increasingly, of intent. Last week, shareholders of Apollo Hospitals Enterprise Limited (AHEL), India’s largest hospital chain, approved a major corporate restructuring. AHEL will de-merge its pharmacy business, Apollo Pharmacy Limited (APL), a country-wide chain of 3,428 pharmacies, effective April 2020. Antitrust regulator Competition Commission of India already gave the go-ahead for the move in September this year. 

The demerger will see three financial investors—Enam Securities, Hemendra Kothari and Jhelum Investments—put Rs 527.8 crore ($74.6 million) on the table for 74.5% of Apollo Pharmacy. The remaining 25.5% stays with the parent, AHEL. 

The kicker, or the footnote going by the lack of public attention, in the deal is that “the back-end business related to the standalone pharmacies which represent 85% of the business economics will continue to be held by AHEL”. 

The question to ask then, is whether it really is a demerger. Or is it a parking exercise? A warehousing deal where the equity is given out, but the economic value is retained? Understandably, many in the healthcare industry are confused. AHEL acknowledged a set of questions from The Ken on 24 October but did not respond. 

“If you are not confused, you are not paying attention,” author Tom Peters said in his best seller Thriving on Chaos. The management guru’s book may be dated, but his wisecrack isn’t. 

Apollo Group’s peers and competitors are paying attention. The largest pharmacy chain in the country is being demerged from the largest hospital chain—a business that contributed Rs 3,886 crore ($549.5 million), or 39% of the consolidated revenue of AHEL in the year ending March 2019. 

The restructuring is a masterstroke that will unlock value for the hospital group that has debt piling up. In the last three or four years, AHEL aggressively expanded with new hospitals that took longer to break even, resulting in over Rs 3,200 crore ($452 million) of debt at the beginning of this year. Promoter shares pledged to unreasonable levels of 78% will now be brought down to 20%, thanks to money from the demerger and divestment of the insurance business that is used to reduce credit crunch. 

As of March, the company’s debt exceeded its net worth. Not surprisingly, last month, the promoters divested 3.6% holding in the hospital to bring down debt and associated pledges, reducing their total shareholding to 30.8%. 

The current share price of AHEL doesn’t reflect the value of the pharmacy chain which is a high ROE (return on equity) business with higher multiples in valuation

A hedge fund manager

AHEL is a complex mesh of 37 subsidiaries and associate companies.


Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at detailing the error or queries.